Chronic pancreatitis is now recognized as a complex fibroinflammatory disorder involving genetic, environmental, and metabolic factors.

Scientists may be on the verge of a major breakthrough in cystic fibrosis treatment. The Cystic Fibrosis Foundation has partnered with biotech company Antiverse to use advanced artificial intelligence ...

Engineers at the University of Pennsylvania and Rice University have refined a technology for editing individual genetic "base pairs" to a new level of precision, opening the door to safer, more ...

A visualization of the A3G editor's crystalline structure, with red arrows indicating locations the engineers modified to change their affinity for binding to DNA. Making the editor more accurate ...

"I live each and every day like it could be my last," the bride, Dannika Evans, tells PEOPLE Courtesy of Dannika Evans Dannika Evans married Bo Evans on June 13 in Sioux Falls, South Dakota The bride ...

A bride didn't let cystic fibrosis hold her back from celebrating her wedding. Since she was diagnosed with cystic fibrosis (CF) at 6 years old, Dannika Evans, now 20, embraces each moment to the ...

Researchers have demonstrated that lipid nanoparticles can package and deliver an entire therapeutic gene along with gene-editing machinery - a combination of large, complex components that non-viral ...

Mutations in the ACVRL1 gene may play a role in the development of idiopathic pulmonary fibrosis (IPF), and targeting the gene — until now, little noted, according to researchers — could potentially ...

Feb 12 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis ...

Vertex Pharmaceuticals logged higher fourth-quarter profit as persistent demand for its cystic fibrosis treatments drove double-digit revenue growth. The biotechnology company reported a ...

Even a disease as deadly as idiopathic pulmonary fibrosis (IPF) can start out as just a cough. But as the condition progresses, a person might experience up to 500 respiratory spasms per day.

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a ...